LEADER 02755nam 2200421z- 450 001 9910137092803321 005 20210211 035 $a(CKB)3710000000824729 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/54188 035 $a(oapen)doab54188 035 $a(EXLCZ)993710000000824729 100 $a20202102d2015 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aMysteries of Type I IFN response: benefits versus detriments 210 $cFrontiers Media SA$d2015 215 $a1 online resource (74 p.) 225 1 $aFrontiers Research Topics 311 08$a2-88919-629-1 330 $aSuccessful containment of an infection is dependent on both innate and adaptive immune response. Cytokines are essential effectors of both of these systems. In particular, type I interferons (IFN-I) are important components of early innate immunity against an infection. However, the production of IFN-I could serve as a double edge sword, either containing an infection or enhancing susceptibility. For example, IFN-I, which is essential for early containment of viral infections, has been shown to be detrimental to the host during bacterial infections. In fact, recent significant reports have shown that influenza virus induced IFN-I responses can enhance the host susceptibility to secondary bacterial infections. These recent reports highlight the expanding immunoregulatory role of IFN-I in the host immunity. With these recent findings in mind, the aim of this research topic is to welcome novel data, opinion and literature reviews on the newly identified dual functions of IFN-I. This research topic wills focus on the following areas of IFN-I: 1) a detrimental role of IFN-I during primary bacterial infection; 2) a detrimental role of viral infection induced IFN-I during secondary bacterial infections; 3) evolutionary pressure that drove detrimental IFN-I response during primary bacterial infection; and 4) does benefit of IFN-I responses during primary viral infections outweigh the adverse consequences of IFN-I mediated enhanced susceptibility to secondary bacterial infections. 517 $aMysteries of Type I IFN response 606 $aMedicine$2bicssc 610 $aadjuvant 610 $aAutoimmunity 610 $abacterial and viral infections 610 $atype I IFN 610 $aVaccine 615 7$aMedicine 700 $aHerbert Patrick Ludewick$4auth$01284050 702 $aArno Mullbacher$4auth 702 $aYoichi Furuya$4auth 906 $aBOOK 912 $a9910137092803321 996 $aMysteries of Type I IFN response: benefits versus detriments$93019236 997 $aUNINA